Author:
Peng Rong,Yang Ting,Tong Yu,Wang Ji,Zhou Hui,Yang Minglong,Zhu Junchen,Yang Lijun,Shi Zheng,Liu Ya
Subject
Public Health, Environmental and Occupational Health,Epidemiology
Reference36 articles.
1. Lescure, F. X., H. Honda, R. A. Fowler, J. S. Lazar, G. Shi, P. Wung, N. Patel, O. Hagino, and Covid-Global Study Group Sarilumab. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet respiratory medicine.2021; 9(5): 522-532. (https://clinicaltrials.gov/ct522/show/results/NCT04327388).
2. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial;Caballero Bermejo;Trials,2020
3. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial;Declercq;Lancet Respir. Med.,2021
4. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes;Deeks;Stat. Med.,2002
5. Clinical Nutrition in Critical Care Medicine – Guideline of the German Society for Nutritional Medicine (DGEM);Elke;Clinical Nutrition ESPEN,2019